Radgocitabine is under clinical development by Delta-Fly Pharma and currently in Phase III for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase III drugs for Refractory Acute Myeloid Leukemia have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Radgocitabine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Radgocitabine (DFP-10917) is under development for the treatment of relapsed and refractory acute leukemias including acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). The drug candidate is administered as an intravenous infusion. It is a deoxycytidine analog that targets G2/M phase of the cell cycle.
Delta-Fly Pharma overview
Delta-Fly Pharma is a biopharmaceutical and healthcare company. The company discovers and develops anti-cancer agents. It’s product portfolio includes DFP-10917, for the treatment of myelogenous leukemia; DFP-14323, an anticancer drug candidate treating lung cancer; DFP-10825, liposome-conjugated RNAi molecule which targets disseminated ovarian and gastric cancer. Delta-Fly Pharma also develops DFP-11207, cancer cell metabolism regulator that treats stomach cancer; DFP-14927, Polymeric anti-cancer agent for the treatment of solid tumors. The company develops novel products using module technology (Module Drug Discovery). It has its operations in Japan, Canada, and China. Delta-Fly Pharma is headquartered in Tokushima-Shi, Tokushima, Japan.
For a complete picture of Radgocitabine’s drug-specific PTSR and LoA scores, buy the report here.